Test blood DNA to find lymphoma changes and leftover disease
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks a blood test that looks for small DNA fragments (“cell-free DNA”) to find cancer changes that could guide treatment in diffuse large B-cell lymphoma. It also looks for “minimal residual disease,” meaning tiny amounts of lymphoma that may remain after treatment, and whether this test works across community cancer centers in Texas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma
- You must agree to take part by signing written consent
- Pregnant people are not allowed
- You must be able to understand and participate (not cognitively impaired)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study looks at “cell-free DNA,” meaning tiny bits of DNA found in blood, in people with mature B-cell lymphoma. It may help doctors understand the disease better and how blood tests could be used to monitor it.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.